Evidence map›Paper›PMID 36369764›Full record

ArticleAnnals of clinical and translational neurology2022

A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice.

Aina Calls, Abel Torres-Espin, Marc Tormo, Laura Martínez-Escardó, Núria Bonet, Ferran Casals, Xavier Navarro, Víctor J Yuste, Esther Udina, Jordi Bruna

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Platinum accumulation in chemotherapy: toxicity mechanisms, challenges, and mitigation strategies.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Aina CallsDepartment of Cell Biology, Physiology, and Immunology, Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID https://orcid.org/0000-0002-8233-456X
Abel Torres-EspinDepartment of Neurological Surgery, Brain and Spinal Injury Center, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-9787-8738
Marc TormoGenomics Core Facility, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
Laura Martínez-EscardóDepartment of Biochemistry, Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID https://orcid.org/0000-0003-2979-4804
Núria BonetGenomics Core Facility, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-0574-2575
Ferran CasalsGenomics Core Facility, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-8941-0369
Xavier NavarroDepartment of Cell Biology, Physiology, and Immunology, Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Víctor J YusteDepartment of Biochemistry, Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID https://orcid.org/0000-0001-5322-9261
Esther UdinaDepartment of Cell Biology, Physiology, and Immunology, Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID https://orcid.org/0000-0003-1954-8562
Jordi BrunaDepartment of Cell Biology, Physiology, and Immunology, Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID https://orcid.org/0000-0001-6895-5047
Universitat Autònoma de Barcelona · ESUniversitat Pompeu Fabra · ESUniversity of California, San Francisco · US

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca FI-DGRCIBERNEDEuropean Social FundEuropean UnionFEDER Una manera de hacer Europa PID2021-125106OB-C32Instituto de Salud Carlos III of Spain PI210018MCIN/AEI RTI2018-096824-B-C22TERCELthe Department of Health of the Government of Catalonia, CERCA Program SLT008/18/00028
6 · The paper itself

Abstract

objectivesPeripheral neuropathy is a relevant dose-limiting adverse event that can affect up to 90% of oncologic patients with colorectal cancer receiving oxaliplatin treatment. The severity of neurotoxicity often leads to dose reduction or even premature cessation of chemotherapy. Unfortunately, the limited knowledge about the molecular mechanisms related to oxaliplatin neurotoxicity leads to a lack of effective treatments to prevent the development of this clinical condition. In this context, the present work aimed to determine the exact molecular mechanisms involved in the development of oxaliplatin neurotoxicity in a murine model to try to find new therapeutical targets.

methodsBy single-cell RNA sequencing (scRNA-seq), we studied the transcriptomic profile of sensory neurons and satellite glial cells (SGC) of the Dorsal Root Ganglia (DRG) from a well-characterized mouse model of oxaliplatin neurotoxicity.

resultsAnalysis of scRNA-seq data pointed to modulation of inflammatory processes in response to oxaliplatin treatment. In this line, we observed increased levels of NF-kB p65 protein, pro-inflammatory cytokines, and immune cell infiltration in DRGs and peripheral nerves of oxaliplatin-treated mice, which was accompanied by mechanical allodynia and decrease in sensory nerve amplitudes.

interpretationOur data show that, in addition to the well-described DNA damage, oxaliplatin neurotoxicity is related to an exacerbated pro-inflammatory response in DRG and peripheral nerves, and open new insights in the development of anti-inflammatory strategies as a treatment for preventing peripheral neuropathy induced by oxaliplatin.

Indexed as

Antineoplastic AgentsNeurotoxicity SyndromesPeripheral Nervous System DiseasesAnimalsGanglia, SpinalMiceOrganoplatinum CompoundsOxaliplatinAntineoplastic AgentsOrganoplatinum CompoundsOxaliplatin

Identifiers

PMID36369764
PMCPMC9735376
OpenAlexW4308796202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.